Immune globulin - CSL Behring

Drug Profile

Immune globulin - CSL Behring

Alternative Names: Beriglobin P; Berirab P; Carimune NF; Gamma Venin P; Hizentra; IgNextGen 10%; IgPro10; IgPro16; IgPro20; IVIG 10% -CSL Behring; Privigen; Redimune; Redimune NF liquid; Rhesogamma P; Rhophylac; Sandoglobulin; Sandoglobulin NF liquid; Tetagam P; Varicellon; Venimmun N; Vivaglobin

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator CSL Behring
  • Developer Assistance Publique Hopitaux de Paris; CSL Behring; Rigshospitalet; University of Oxford
  • Class Immunoglobulins; Immunoproteins; Serum globulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Chronic inflammatory demyelinating polyradiculoneuropathy; Guillain-Barre syndrome; Haemolytic disease of newborn; Hepatitis A; Hepatitis B; Immune thrombocytopenic purpura; Immunodeficiency disorders; Mucocutaneous lymph node syndrome; Rabies; Tetanus; Varicella zoster virus infections
  • Phase III Encephalitis; Renal transplant rejection
  • Phase II Skin and soft tissue infections
  • No development reported Motor neuron disease; Systemic lupus erythematosus

Most Recent Events

  • 01 Sep 2016 CSL Behring completes a phase III clinical trial for Chronic inflammatory demyelinating polyradiculoneuropathy in USA, Australia, Canada, Estonia, Finland, France, Germany, Italy, Japan, Netherlands, Poland, Spain, Belgium, Czech Republic, Israel and United Kingdom (NCT01545076)
  • 01 Sep 2016 CSL Behring and Rigshospitalet completes a phase II trial in Skin and soft tissue infections in Denmark (NCT02111161)
  • 16 Jul 2016 No recent reports of development identified for research development in Systemic-lupus-erythematosus in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top